Revance Therapeutics (RVNC) 10-Q 10 May 21 2021 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2021	Apr. 27, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	001-36297
Entity Registrant Name	Revance Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0551645
Entity Address, Address Line One	1222 Demonbreun Street, Suite 1001
Entity Address, City or Town	Nashville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37203
City Area Code	615
Local Phone Number	724-7755
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	RVNC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		71,529,367
Entity Central Index Key	0001479290
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 249,427	$ 333,558
Short-term investments	137,386	102,947
Accounts and other receivables, net	5,186	1,829
Inventories	5,629	5,876
Prepaid expenses and other current assets	8,799	5,793
Total current assets	406,427	450,003
Property and equipment, net	20,766	17,499
Goodwill	146,964	146,964
Intangible assets, net	67,837	71,343
Operating lease right of use assets	28,779	29,632
Restricted cash	3,445	3,445
Other non-current assets	1,729	1,334
TOTAL ASSETS	675,947	720,220
CURRENT LIABILITIES
Accounts payable	7,079	12,657
Accruals and other current liabilities	27,101	32,938
Deferred revenue, current portion	9,046	7,851
Operating lease liabilities, current portion	4,472	4,437
Derivative liability	3,140	3,081
Total current liabilities	50,838	60,964
Convertible senior notes	279,694	180,526
Deferred revenue, net of current portion	74,967	77,294
Operating lease liabilities, net of current portion	26,201	27,146
TOTAL LIABILITIES	431,700	345,930
Commitments and Contingencies
STOCKHOLDERS’ EQUITY
Convertible preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2021 and December 31, 2020	0	0
Common stock, par value $0.001 per share — 95,000,000 shares authorized both as of March 31, 2021 and December 31, 2020; 71,411,389 and 69,178,666 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	71	69
Additional paid-in capital	1,432,457	1,500,514
Accumulated deficit	(1,188,281)	(1,126,293)
TOTAL STOCKHOLDERS’ EQUITY	244,247	374,290
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 675,947	$ 720,220

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock authorized (in shares)	95,000,000	95,000,000
Common stock, shares issued (in shares)	71,411,389	69,178,666
Common stock, shares outstanding (in shares)	71,411,389	69,178,666

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue:
Total Revenue	$ 13,299	$ 58
Operating expenses:
Selling, general and administrative	49,005	21,224
Research and development	27,251	39,794
Amortization	2,838	0
Total operating expenses	83,311	61,018
Loss from operations	(70,012)	(60,960)
Interest income	97	1,491
Interest expense	(1,560)	(2,148)
Changes in fair value of derivative liability	(59)	(90)
Other expense, net	(105)	(126)
Loss before income taxes	(71,639)	(61,833)
Income tax provision	0	(100)
Net loss	(71,639)	(61,933)
Unrealized gain and adjustment on securities included in net loss	0	521
Comprehensive loss	(71,639)	(61,412)
Basic net loss	(71,639)	(61,933)
Diluted net loss	$ (71,639)	$ (61,933)
Basic net loss (in dollars per share)	$ (1.08)	$ (1.15)
Diluted net loss (in dollars per share)	$ (1.08)	$ (1.15)
Basic weighted-average number of shares used in computing net loss per share (in shares)	66,636,830	53,868,036
Diluted weighted-average number of shares used in computing net loss per share (in shares)	66,636,830	53,868,036
Product revenue
Revenue:
Total Revenue	$ 11,647	$ 0
Operating expenses:
Cost of product revenue /service revenue (exclusive of amortization)	4,217	0
Collaboration revenue
Revenue:
Total Revenue	1,511	58
Service revenue
Revenue:
Total Revenue	141	0
Operating expenses:
Cost of product revenue /service revenue (exclusive of amortization)	$ 0	$ 0

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Additional Paid-In CapitalCumulative Effect, Period of Adoption, Adjustment	Other Accumulated Comprehensive Gain	Accumulated Deficit	Accumulated DeficitCumulative Effect, Period of Adoption, Adjustment
Beginning Balance (in shares) at Dec. 31, 2019		0	52,374,735	0		0	0
Beginning Balance at Dec. 31, 2019		$ 0	$ 52	$ 1,069,639		$ 3	$ (844,204)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock awards, net of cancellation (in shares)			1,197,054
Issuance of restricted stock awards and performance stock awards, net of cancellation			$ 1	(1)
Issuance of common stock in connection with at-the-market offerings				0
Issuance of common stock upon exercise of stock options and warrants (in shares)			52,352
Net settlement of restricted stock awards for employee taxes (in shares)			(72,987)
Issuance of common stock upon exercise of stock options and warrants				572
Shares withheld related to net settlement of restricted stock awards				(1,401)
Issuance of common stock in connection with the teoxane agreement (in shares)			2,500,000
Issuance of common stock in connection with the Teoxane Agreement			$ 3	43,397
Stock-based compensation				6,544
Equity component of convertible senior notes				108,510
Issuance of common stock in connection with offerings (in shares)			975,000
Issuance of common stock in connection with offerings			$ 1	15,536
Capped call transactions related to the issuance of convertible senior notes				$ (28,865)
Unrealized gain and adjustment on securities included in net loss	$ 521					$ 521
Net loss	$ (61,933)						$ (61,933)
Ending Balance (in shares) at Mar. 31, 2020	57,026,154		57,026,154	0		0	0
Ending Balance at Mar. 31, 2020	$ 308,375		$ 57	$ 1,213,931		$ 524	$ (906,137)
Beginning Balance (in shares) at Dec. 31, 2019		0	52,374,735	0		0	0
Beginning Balance at Dec. 31, 2019		$ 0	$ 52	$ 1,069,639		$ 3	$ (844,204)
Ending Balance (in shares) at Dec. 31, 2020	69,178,666	0	69,178,666	0		0	0
Ending Balance at Dec. 31, 2020	$ 374,290	$ 0	$ 69	$ 1,500,514	$ (108,509)	$ 0	$ (1,126,293)	$ 9,651
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	rvnc:AccountingStandardsUpdate202006Member
Issuance of restricted stock awards, net of cancellation (in shares)			869,586
Issuance of restricted stock awards and performance stock awards, net of cancellation			$ 1	(1)
Issuance of common stock in connection with offerings (in shares)			761,526
Issuance of common stock in connection with at-the-market offerings			$ 1	21,700
Issuance of common stock upon exercise of stock options and warrants (in shares)			729,438
Net settlement of restricted stock awards for employee taxes (in shares)			(127,827)
Issuance of common stock upon exercise of stock options and warrants				11,136
Shares withheld related to net settlement of restricted stock awards				(3,645)
Stock-based compensation				$ 11,262
Unrealized gain and adjustment on securities included in net loss	$ 0
Net loss	$ (71,639)						$ (71,639)
Ending Balance (in shares) at Mar. 31, 2021	71,411,389		71,411,389	0		0	0
Ending Balance at Mar. 31, 2021	$ 244,247		$ 71	$ 1,432,457		$ 0	$ (1,188,281)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock issuance costs	$ 153	$ 337
Follow on Public Offering
Stock issuance costs	$ 44	$ 44

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (71,639)	$ (61,933)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	10,607	6,544
Depreciation and amortization	4,241	739
Amortization of debt discount and issuance costs	310	1,505
Amortization of discount on investments	(55)	(513)
Other non-cash operating activities	59	371
Non-cash in-process research and development	0	11,184
Changes in operating assets and liabilities:
Accounts and other receivables	(3,357)	0
Inventories	247	0
Prepaid expenses and other current assets	(3,006)	(467)
Operating lease right of use assets	853	570
Other non-current assets	(395)	175
Accounts payable	(4,996)	789
Accruals and other liabilities	(5,582)	(2,373)
Deferred revenue	(1,132)	942
Operating lease liabilities	(910)	(822)
Net cash used in operating activities	(74,755)	(43,289)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments	(87,384)	(159,412)
Purchases of property and equipment	(4,036)	(539)
Proceeds from maturities of investments	53,000	54,500
Purchase of intangible assets	0	(118)
Net cash used in investing activities	(38,420)	(105,569)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock in connection with at-the-market offerings, net of commissions	21,706	0
Proceeds from the exercise of stock options and common stock warrants	11,136	572
Taxes paid related to net settlement of restricted stock awards	(3,645)	(1,401)
Payment of offering costs	(153)	(337)
Proceeds from issuance of convertible senior notes	0	287,500
Proceeds from issuance of common stock in connection with offerings, net of commissions and discount	0	15,581
Payment of capped call transactions	0	(28,865)
Payment of convertible senior notes transaction costs	0	(8,703)
Net cash provided by financing activities	29,044	264,347
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(84,131)	115,489
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period	337,003	171,890	$ 171,890
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period	252,872	287,379	$ 337,003
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Internally developed software capitalized from stock-based compensation	655	0
Property and equipment purchases included in accounts payable and accruals	213	247
Accrued offering costs	40	0
Issuance of common stock in connection with the Teoxane Agreement	0	43,400
Accrued transaction costs on convertible senior notes	$ 0	$ 487

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Summary of Significant Accounting Policies	The Company and Summary of Significant Accounting Policies The Company Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. We have successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and are pursuing United States (“U.S.”) regulatory approval. We are also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in two therapeutic indications—cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, we own a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to Teoxane SA (“Teoxane”)’s line of Resilient Hyaluronic Acid® (“RHA®”) Collection of dermal fillers, the first and only range of U.S. Food and Drug Administration (the “FDA”)-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform (the “HintMD platform”), which provides an integrated smart payment solution that supports aesthetic practice management, practice economics and practice loyalty. We have also partnered with Viatris Inc. (formerly Mylan N.V.) (“Viatris”) to develop a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX® (“an onabotulinumtoxinA biosimilar”), which would compete in the existing short-acting neuromodulator marketplace. We are dedicated to making a difference by transforming patient experiences. On July 23, 2020, we completed the acquisition of all of the issued and outstanding shares of Hint, Inc. (d/b/a HintMD) (the “HintMD Acquisition”), and HintMD became a wholly owned subsidiary of Revance. The HintMD platform provides a seamless, simple and smart payment solution that enables medical aesthetic practices to improve practice management and economics and foster loyalty with customers, which completes the value chain of our aesthetics portfolio and aligns with our goal to improve outcomes for patients and practices. The HintMD Acquisition leverages our existing and planned commercial infrastructure, and, we believe this financial technology service offering will enable us to grow our U.S. aesthetics business. Since inception, we have devoted substantial efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, raising capital, conducting preclinical and clinical development of, and manufacturing development for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, the onabotulinumtoxinA biosimilar, and the commercial launch of our products and services. We have incurred losses and negative cash flows from operations. We have not generated substantial revenue to date, and will continue to incur significant research and development, sales and marketing, and other expenses related to our ongoing operations. For the three months ended March 31, 2021, we had a net loss of $71.6 million. As of March 31, 2021, we had a working capital surplus of $355.6 million and an accumulated deficit of $1.2 billion. In recent years, we have funded our operations primarily through the sale of common stock, convertible senior notes, and payments received from collaboration arrangements. As of March 31, 2021, we had capital resources of $386.8 million consisting of cash, cash equivalents, and short-term investments. We believe that our existing capital resources will fund our operating plan through at least the next 12 months following the issuance of this Report, and we may identify additional capital resources to fund our operations. Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. Our condensed consolidated balance sheet for the year ended December 31, 2020 was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2021, or any other future period. Our condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission (the “SEC”), on February 25, 2021. Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. All intercompany transactions have been eliminated. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, the fair value of assets and liabilities assumed in business combinations, incremental borrowing rate used to measure operating lease liabilities, the recoverability of goodwill and long-lived assets, useful lives associated with property and equipment and intangible assets, period of benefit associated with deferred costs, useful lives of customer contracts, revenue recognition (including the timing of satisfaction of performance obligations, estimating variable consideration, estimating stand-alone selling prices of promised goods and services, and allocation of transaction price to performance obligations), deferred revenue classification, accruals including clinical trial costs, valuation and assumptions underlying stock-based compensation and other equity instruments, fair value of derivative liability, fair value of the liability component of the convertible senior notes, allocation of purchase consideration in asset acquisitions, and income taxes. The ongoing COVID-19 pandemic has caused a global slowdown of economic activity which has negatively impacted consumer spending, including with respect to our current and potential customers, while also disrupting sales channels and marketing activities. In November 2020, the FDA deferred a decision on the biologics license application (“BLA”) for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines. The FDA reiterated that an inspection of our manufacturing facility is required as part of the BLA approval process, but the FDA was unable to conduct the required inspection of our manufacturing facility in Newark, California, due to the FDA’s travel restrictions associated with the COVID-19 pandemic. We are unable to predict the future impact of the COVID-19 pandemic on the FDA inspection required for the approval of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines, the progress of clinical trials, supplies and sales of the RHA® Collection of dermal fillers, demand for our products and other aspects of our operations. As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements. Recently Adopted Accounting Pronouncement In August 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . The amendments in ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 simplifies the accounting for convertible debt instruments by removing certain requirements to separately account for conversion options embedded in debt instruments that are not required to be accounted for as derivative instruments. ASU 2020-06 also updates and improves the consistency of earnings per share calculations for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. On January 1, 2021, we adopted ASU 2020-06 using the modified retrospective method and the adoption did not have any impact for our consolidated balance sheets as of December 31, 2020. As a result of the adoption, on January 1, 2021, we made certain adjustments on our consolidated balance sheets which consisted of an increase of $98.9 million in Convertible Senior Notes (the 2027 Notes as defined in Note 9 ), a decrease of $108.5 million in Additional Paid-in Capital and a decrease of $9.7 million in Accumulated Deficit. Additionally, from January 1, 2021, we will no longer incur non-cash interest expense for the amortization of debt discount after adoption, therefore the interest expense for the 2027 Notes, which is included in the Interest Expense on the condensed consolidated statements of operations and comprehensive loss, will be lower comparing to fiscal year 2020. Recent Accounting Pronouncements The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Our revenue is primarily generated from U.S. customers. Our product and collaboration revenue is generated from the Product Segment, and our service revenue is generated from the Service Segment ( Note 13 ). The following tables present our revenues disaggregated by the timing of transfer of goods or services: Three Months Ended March 31, 2021 (in thousands) Product Revenue Collaboration Revenue Service Revenue Total Timing of revenue recognition: Transferred at a point in time $ 11,647 $ — $ — $ 11,647 Transferred over time — 1,511 141 1,652 Total $ 11,647 $ 1,511 $ 141 $ 13,299 For the three months ended March 31, 2020, we had no product or service revenue, and our collaboration revenue of $58 thousand was transferred over time. Product Revenue For the three months ended March 31, 2021, all product revenue was generated from the sale of the RHA® Collection of dermal fillers. Collaboration Revenue Viatris Collaboration and License Agreement Agreement Terms We entered into a collaboration and license agreement with Viatris (the “Viatris Collaboration”) in February 2018, pursuant to which we are collaborating with Viatris exclusively, on a world-wide basis (excluding Japan), to develop, manufacture, and commercialize an onabotulinumtoxinA biosimilar. Viatris has paid us an aggregate of $60 million in non-refundable fees as of March 31, 2021, and the agreement provides for additional remaining contingent payments of up to $70 million in the aggregate, upon the achievement of certain clinical and regulatory milestones and of specified, tiered sales milestones of up to $225 million. The payments do not represent a financing component for the transfer of goods or services. Revenue Recognition We re-evaluate the transaction price at each reporting period. We estimated the transaction price for the Viatris Collaboration using the most likely amount method. In order to determine the transaction price, we evaluated all of the payments to be received during the duration of the contract, which included milestones and consideration payable by Viatris. Other than the upfront payment, all other milestones and consideration we may earn under the Viatris Collaboration are subject to uncertainties related to development achievements, Viatris’ rights to terminate the agreement, and estimated effort for cost-sharing payments. Components of such estimated effort for cost-sharing payments include both internal and external costs. Consequently, the transaction price does not include any milestones and considerations that, if included, could result in a probable significant reversal of revenue when related uncertainties become resolved. Sales-based milestones and royalties are not included in the transaction price until the sales occur because the underlying value relates to the license and the license is the predominant feature in the Viatris Collaboration. As of March 31, 2021, the transaction price allocated to the unfulfilled performance obligations was $102.7 million. We recognize revenue and estimate deferred revenue based on the cost of development service incurred over the total estimated cost of development service to be provided for the development period. For revenue recognition purposes, the development period is estimated to continue through 2025. It is possible that this period will change and is assessed at each reporting date. For the three months ended March 31, 2021 and 2020, we recognized revenue related to development services of $1.5 million and $0.1 million, respectively. As of March 31, 2021 and December 31, 2020, we estimated short-term deferred revenue of $9.0 million and $7.9 million, respectively; and long-term deferred revenue of $44.0 million and $46.3 million, respectively. Fosun License Agreement Agreement Terms In December 2018, we entered into a license agreement (the “Fosun License Agreement”) with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun”), whereby we granted Fosun the exclusive rights to develop and commercialize our proprietary DaxibotulinumtoxinA for Injection in mainland China, Hong Kong and Macau (the “Fosun Territory”) and certain sublicense rights. Fosun has paid us non-refundable upfront and other payments totaling $31.0 million before foreign withholding taxes. We are also eligible to receive (i) additional remaining contingent payments of up to $229.5 million upon the achievement of certain milestones based on (a) the approval of BLAs for certain aesthetic and therapeutic indications and (b) first calendar year net sales, and (ii) tiered royalty payments in low double digits to high teen percentages on annual net sales. The royalty percentages are subject to reduction in the event that (i) we do not have any valid and unexpired patent claims that cover the product in the Fosun Territory, (ii) biosimilars of the product are sold in the Fosun Territory or (iii) Fosun needs to pay compensation to third parties to either avoid patent infringement or market the product in the Fosun Territory. Revenue Recognition We estimated the transaction price for the Fosun License Agreement using the most likely amount method. We evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered. We will re-evaluate the transaction price at each reporting period and upon a change in circumstances. As of March 31, 2021, the transaction price allocated to unfulfilled performance obligation was $31.0 million. For the three months ended March 31, 2021 and 2020, no revenue was recognized from the Fosun License Agreement. Substantially all payments received to date were included in long-term deferred revenue as of March 31, 2021 and December 31, 2020. Service Revenue Following the HintMD Acquisition in July 2020, we began to offer customer payment processing and certain value-added services through our HintMD platform to aesthetic practices. Revenue related to the payment processing service is recognized at a point in time, whereas revenue related to the value-added services is recognized over time.

Cash Equivalents and Short-Term

Cash Equivalents and Short-Term Investments	3 Months Ended
	Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Cash Equivalents and Short-Term Investments	Cash Equivalents and Short-Term Investments The following table is a summary our cash equivalents and short-term investments: March 31, 2021 December 31, 2020 in thousands Cost Fair Value Cost Fair Value Money market funds $ 243,266 $ 243,266 $ 267,130 $ 267,130 Commercial paper 137,386 137,386 113,446 113,446 Total cash equivalents and available-for-sale securities $ 380,652 $ 380,652 $ 380,576 $ 380,576 Classified as: Cash equivalents $ 243,266 $ 277,629 Short-term investments 137,386 102,947 Total cash equivalents and available-for-sale securities $ 380,652 $ 380,576 As of March 31, 2021 and December 31, 2020, we have no other-than-temporary impairments on our available-for-sale securities, and the contractual maturities of the available-for-sale securities are less than one-year.

Intangible Assets, net

Intangible Assets, net	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net The following table sets forth the intangible assets and the remaining useful lives for the intangible assets: March 31, 2021 December 31, 2020 (in thousands, except for in years) Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Distribution rights 3.2 $ 32,334 $ (6,736) $ 25,598 3.4 $ 32,334 $ (4,715) $ 27,619 Developed technology 5.3 19,600 (2,178) 17,422 5.6 19,600 (1,362) 18,238 In-process research and development (1) N/A 16,200 — 16,200 N/A 16,200 — 16,200 Customer relationships 3.3 10,300 (1,717) 8,583 3.6 10,300 (1,072) 9,228 Tradename 0.3 100 (66) 34 0.6 100 (42) 58 Total intangible assets $ 78,534 $ (10,697) $ 67,837 $ 78,534 $ (7,191) $ 71,343 (1) In-process research and development relates to the research and development of payment facilitator technology to facilitate the processing of customer payments. As of March 31, 2021, no amortization expense has been recorded as the assets have not yet been completed and placed into service. Upon completion of the associated research and development activities, the assets' useful lives will be determined. Prior to completion of certain research and development activities, these intangible assets will be subject to annual impairment tests, or more frequent tests in the event of any impairment indicators occurring. These impairment tests require significant judgment regarding the status of the research activities, the potential for future revenues to be derived from any products that may result from those activities, and other factors. For the three months ended March 31, 2021, the aggregate amortization expense of intangible assets was $3.5 million, of which $2.8 million was recorded to “Amortization” in the condensed consolidated statement of operations and comprehensive loss and it was related to the amortization of Distribution rights and Developed technology, the remaining $0.7 million was recorded to “Selling, general and administrative” in the condensed consolidated statement of operations and comprehensive loss. No amortization expense of intangible assets was recorded for the three months ended March 31, 2020. Based on the amount of intangible assets subject to amortization as of March 31, 2021, the estimated amortization expense for each of the next five fiscal years and thereafter was as follows: Year Ending December 31, (in thousands) 2021 remaining nine months $ 10,477 2022 13,925 2023 13,925 2024 8,137 2025 3,267 2026 and thereafter 1,906 Total $ 51,637

Inventories

Inventories	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventories	InventoriesAs of March 31, 2021 and December 31, 2020, we had inventories of $5.6 million and $5.9 million, respectively, which were finished goods from purchased RHA® Collection of dermal fillers.

Balance Sheet Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Balance Sheet Components	Balance Sheet Components Accruals and Other Current Liabilities Accruals and other current liabilities consist of the following: March 31, December 31, (in thousands) 2021 2020 Accruals related to: Compensation $ 13,940 $ 17,374 General expenses 6,052 5,683 Clinical trials 3,052 3,726 Interest expense 629 1,887 Inventories 215 1,796 Other current liabilities 2,213 1,472 Nonrecurring milestone payment 1,000 1,000 Total $ 27,101 $ 32,938 Property and Equipment, net Property and equipment, net consists of the following: March 31, December 31, (in thousands) 2021 2020 Manufacturing equipment $ 19,937 $ 19,810 Leasehold improvements 5,978 5,972 Platform software (1) 5,369 3,388 Other construction in progress 3,210 1,539 Computer software 2,972 2,972 Computer equipment 1,909 1,768 Furniture and fixtures 1,616 1,541 Total property and equipment 40,991 36,990 Less: Accumulated depreciation and amortization (20,225) (19,491) Property and equipment, net $ 20,766 $ 17,499 (1) The platform software was not placed in service as of both March 31, 2021 and December 31, 2020.

Derivative Liability

Derivative Liability	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Derivative Liability	Derivative Liability In 2012, we entered into a settlement agreement in which we are obligated to pay $4.0 million upon achieving regulatory approval for DaxibotulinumtoxinA for Injection or DaxibotulinumtoxinA Topical. We determined that such payment was a derivative instrument that requires fair value accounting as a liability and periodic fair value remeasurements until settled. The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor. As of March 31, 2021, the fair value of the derivative liability was $3.1 million, which was measured using a term of 0.3 years based on an expected BLA approval in 2021, a risk-free rate of 0.03% and a credit risk adjustment of 7.5%. As of December 31, 2020, the fair value of the derivative liability was $3.1 million, which was measured using a term of 0.5 years based on an expected BLA approval in 2021, a risk-free rate of 0.1% and a credit risk adjustment of 7.5%.

Leases

Leases	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Leases	Leases We have non-cancelable operating leases for facilities related to research, manufacturing, and administrative functions, and equipment operating leases. As of March 31, 2021, the weighted average remaining lease term is 5.8 years. The monthly payments for the facility leases escalate over the facility lease terms with the exception of a decrease in payments at the beginning of 2022. We have options to extend certain facility operating leases for up to 14 years. Our lease contracts do not contain termination options, residual value guarantees or restrictive covenants. The operating lease costs are summarized as follows: Three Months Ended March 31, (in thousands) 2021 2020 Operating lease cost $ 1,704 $ 1,425 Variable lease cost (1) 283 77 Total operating lease costs $ 1,987 $ 1,502 (1) Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred. As of March 31, 2021, maturities of our operating lease liabilities are as follows: Year Ending December 31, (in thousands) 2021 remaining nine months $ 5,888 2022 6,613 2023 6,741 2024 6,952 2025 7,165 2026 and thereafter 8,003 Total operating lease payments 41,362 Less imputed interest (1) (10,689) Present value of operating lease payments $ 30,673 (1) Our lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of 11.4%, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates. Supplemental cash flow information related to the operating leases was as follows: Three Months Ended March 31, (in thousands) 2021 2020 Cash paid for amounts included in the measurement of operating lease liabilities $ 1,761 $ 1,677 Leases Not Yet Commenced In November 2020, we entered into a non-cancelable operating lease for an office space in Nashville, Tennessee. The arrangement also provides a temporary space that does not qualify as a lease. As of March 31, 2021, the accounting commencement date of the primary office lease had not occurred and is expected to take place when the office space is made available to us after the completion of certain improvement work, which is expected in June 2021. The lease has a term of 150 months from the commencement date defined in the lease. We have an option to extend the lease for one seven-year term. The monthly base rent payments for the lease escalate over the term. The total undiscounted base rent payments determinable are $22.9 million.

Convertible Senior Notes

Convertible Senior Notes	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Convertible Senior Notes	Convertible Senior Notes On February 14, 2020, we issued $287.5 million aggregate principle amount of convertible senior notes that are due in 2027 (the “2027 Notes”) pursuant to an indenture, dated February 14, 2020, between Revance and U.S. Bank National Association, as trustee (the “Indenture”). The 2027 Notes are senior unsecured obligations and bear interest at a rate of 1.75% per year, payable semiannually in arrears on February 15 and August 15 of each year, beginning on August 15, 2020. The 2027 Notes will mature on February 15, 2027, unless earlier converted, redeemed or repurchased. In connection with issuing the 2027 Notes, we received $278.3 million in net proceeds, after deducting the initial purchasers’ discount, commissions, and other issuance costs. A portion of the net proceeds from the 2027 Notes were used to purchase the capped call transactions described below and the remainder will be used to fund expenses associated with commercial launch activities for both the RHA® Collection of dermal fillers and, if approved, DaxibotulinumtoxinA for Injection for glabellar lines, research and development, and other corporate activities. The 2027 Notes may be converted at any time by the holders prior to the close of business on the business day immediately preceding November 15, 2026 only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending on June 30, 2020 (and only during such fiscal quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the 2027 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (3) if we call any or all of the 2027 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after November 15, 2026 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 2027 Notes at any time, regardless of the foregoing circumstances. Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. The conversion rate will initially be 30.8804 shares of our common stock per $1,000 principal amount of the 2027 Notes (equivalent to an initial conversion price of approximately $32.38 per share of our common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or if we deliver a notice of redemption, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2027 Notes in connection with such a corporate event or notice of redemption, as the case may be. Contractually, we may not redeem the 2027 Notes prior to February 20, 2024. We may redeem for cash all or any portion of the 2027 Notes, at our option, on or after February 20, 2024 if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2027 Notes. If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or any portion of their 2027 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. Prior to adoption of ASU 2020-06 on January 1, 2021 ( Note 1 ), we separated the 2027 Notes into liability and equity components. The carrying amount of the liability component was $175.4 million, which was calculated by using a discount rate of 9.5%, which was estimated to be our borrowing rate on the issuance date for a similar debt instrument without the conversion feature. The carrying amount of the equity component was $112.1 million, which represents the conversion option, and was determined by deducting the fair value of the liability component from the par value of the 2027 Notes. The equity component of the 2027 Notes is included in additional paid-in capital in the condensed consolidated balance sheets and will not be subsequently remeasured as long as it continues to meet the conditions for equity classification. The difference between the principal amount of the 2027 Notes and the liability component (the “debt discount”) is amortized to interest expense in the condensed consolidated statements of operations and comprehensive loss using the effective interest method over the term of the 2027 Notes. Total transaction costs for the issuance of the 2027 Notes were $9.2 million, consisting of the initial purchasers’ discount, commissions, and other issuance costs. Prior to adoption of ASU 2020-06 we allocated the total transaction costs proportionally to the liability and equity components. The transaction costs attributed to the liability component were $5.6 million, which were recorded as debt issuance costs (presented as contra debt in our condensed consolidated balance sheets) and are amortized to interest expense in the condensed consolidated statements of operations and comprehensive loss over the term of the 2027 Notes. The transaction costs attributed to the equity component were $3.6 million, which were included in additional paid-in capital. As a result of the early adoption of ASU 2020-06 ( Note 1 ), we reclassified the equity component associated with the 2027 Notes principle and transaction costs from the additional paid-in capital to the convertible senior notes on the condensed consolidated balance sheet. Debt discount was eliminated and the adjustment to the interest expenses was recorded in the accumulated deficit on the condensed consolidated balance sheets. Interest expense relating to the 2027 Notes in the condensed consolidated statements of operations and comprehensive loss are summarized as follows: Three Months Ended (in thousands) March 31, 2021 March 31, 2020 Contractual interest expense $ 1,258 $ 643 Amortization of debt issuance costs 310 44 Amortization of debt discount (1) — 1,461 Total interest expense $ 1,568 $ 2,148 (1) The effective interest rate on the liability component of the 2027 Notes was 9.5% for the year ended December 31, 2020, which remained unchanged from the issuance date. As of December 31, 2020, the unamortized debt discount was $101.7 million and will be amortized over 6.1 years. Due to the adoption of ASU 2020-06 ( Note 1 ), debt discount was eliminated on January 1, 2021 therefore we no longer amortize debt discount. As of March 31, 2021 and December 31, 2020, the convertible senior notes on the condensed consolidated balance sheet represented the carrying amount of the liability component of the 2027 Notes, net of unamortized debt discounts and debt issuance costs (as applicable), which are summarized as follows: March 31, December 31, (in thousands) 2021 2020 2027 Notes $ 287,500 $ 287,500 Less: Unamortized debt issuance costs (7,806) (5,275) Less: Unamortized debt discount — (101,699) Carrying amount of 2027 Notes $ 279,694 $ 180,526 Capped Call Transactions Concurrently with the 2027 Notes, we entered into capped call transactions with one of the initial purchasers and another financial institution (the “option counterparties”) and used $28.9 million of the net proceeds from the 2027 Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce the potential dilutive effect upon conversion of the 2027 Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted 2027 Notes, as the case may be, with such reduction and/or offset subject to a price cap of $48.88 of our common stock per share, which represents a premium of 100% over the last reported sale price of our common stock on February 10, 2020. The cap ped calls have an initial strike price of $32.38 per share, subject to certain adjustments, which corresponds to the conversion option strike price in the 2027 Notes. The capped call transactions cover, subject to anti-dilution adjustments, approximately 8.9 million shares of our common stock. The capped call transactions are separate transactions that we entered into with the option counterparties and are not part of the terms of the 2027 Notes. As the capped call transactions meet certain accounting criteria, the premium paid of $28.9 million was recorded as a reduction in additional paid-in capital in the condensed consolidated balance sheets, and will not be remeasured to fair value as long as the accounting criteria continue to be met. As of March 31, 2021 and December 31, 2020, we had not purchased any shares under the capped call transactions.

Stockholders' Equity and Stock-

Stockholders' Equity and Stock-Based Compensation	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Stockholders' Equity and Stock-Based Compensation	Stockholders’ Equity and Stock-Based Compensation 2014 Equity Incentive Plan (the “2014 EIP”) On January 1, 2021, the number of shares of common stock reserved for issuance under the 2014 EIP increased by 2,767,146 shares. For the three months ended March 31, 2021, 501,982 stock options and 932,827 restricted stock awards, including 234,350 performance stock awards, were granted under the 2014 EIP. As of March 31, 2021, 2,492,257 shares were available for issuance under the 2014 EIP. 2014 Inducement Plan (the “2014 IN”) For the three months ended March 31, 2021, 104,090 restricted stock awards were granted under the 2014 IN. As of March 31, 2021, 485,425 shares were available for issuance under the 2014 IN. HintMD Plan On July 23, 2020, in connection with the HintMD Acquisition, we registered 1,260,946 shares under the Hint, Inc. 2017 Equity Incentive Plan (the “HintMD Plan”). For the three months ended March 31, 2021, no stock options and no restricted stock awards were granted under the HintMD Plan. As of March 31, 2021, 427,313 shares were available for issuance under the HintMD Plan. 2014 Employee Stock Purchase Plan (the “2014 ESPP”) On January 1, 2021, the number of shares of common stock reserved for issuance under the 2014 ESPP increased by 300,000 shares. As of March 31, 2021, 1,909,800 shares were available for issuance under the 2014 ESPP. Net Loss per Share Our basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, which includes the vested restricted stock awards. The diluted net loss per share is calculated by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, underlying shares of convertible senior notes at the initial conversion price, outstanding stock options, outstanding common stock warrants, unvested restricted stock awards and performance stock awards, and shares of common stock expected to be purchased under 2014 ESPP are considered common stock equivalents, which were excluded from the computation of diluted net loss per share because including them would have been antidilutive. Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below: March 31, 2021 2020 Convertible senior notes 8,878,938 8,878,938 Outstanding common stock options 5,004,596 5,305,185 Unvested restricted stock awards and performance stock awards 4,083,686 2,799,982 Shares of common stock expected to be purchased on June 30 under the 2014 ESPP 100,769 49,861 At-The-Market Offering In November 2020, we entered into a sales agreement with Cowen and Company, LLC (“Cowen”) as sales agent (the “2020 ATM Agreement”). Under 2020 ATM Agreement, we may offer and sell, from time to time, through Cowen, shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $125 million. We are not obligated to sell any shares under the 2020 ATM Agreement. Subject to the terms and conditions of the 2020 ATM Agreement, Cowen will use commercially reasonable efforts, consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of The Nasdaq Global Market, to sell shares from time to time based upon our instructions, including any price, time or size limits specified by us. We pay Cowen a commission of up to 3% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. The 2020 ATM Agreement may be terminated by Cowen or us at any time upon notice to the other party, or by Cowen at any time in certain circumstances, including the occurrence of a material and adverse change in our business or financial condition that makes it impractical or inadvisable to market the shares or to enforce contracts for the sale of the shares. For the three months ended March 31, 2021, we sold 761,526 shares of common stock under the 2020 ATM Agreement at a weighted average price of $29.09 per share resulting in net proceeds of $21.7 million after sales agent commissions and offering costs. No shares of common stock were sold under the 2020 ATM Agreement after the filing of our 2020 Form 10-K dated February 25, 2021. As of March 31, 2021, we had $32.6 million available under the 2020 ATM Agreement. For the year ended December 31, 2020, we sold 2,585,628 shares of common stock under the 2020 ATM Agreement at a weighted average price of $27.18 per share resulting in net proceeds of $68.2 million after sales agent commissions and offering costs. Stock-based Compensation Stock-based compensation expense was allocated as follows: (in thousands) Three Months Ended March 31, 2021 2020 Selling, general and administrative $ 7,281 $ 4,102 Research and development 3,326 2,442 Total stock-based compensation $ 10,607 $ 6,544

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy. March 31, 2021 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 243,266 $ 243,266 $ — $ — Commercial paper 137,386 — 137,386 — Total assets measured at fair value $ 380,652 $ 243,266 $ 137,386 $ — Liabilities Derivative liability $ 3,140 $ — $ — $ 3,140 Total liabilities measured at fair value $ 3,140 $ — $ — $ 3,140 December 31, 2020 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 267,130 $ 267,130 $ — $ — Commercial paper 113,446 — 113,446 — Total assets measured at fair value $ 380,576 $ 267,130 $ 113,446 $ — Liabilities Derivative liability $ 3,081 $ — $ — $ 3,081 Total liabilities measured at fair value $ 3,081 $ — $ — $ 3,081 For Level 1 investments, we use quoted prices in active markets for identical assets to determine the fair value. For Level 2 investments, we use quoted prices for similar assets sourced from certain third-party pricing services. The third-party pricing services generally utilize industry standard valuation models for which all significant inputs are observable, either directly or indirectly, to estimate the price or fair value of the securities. The primary input generally includes reported trades of or quotes on the same or similar securities. We do not make additional judgments or assumptions made to the pricing data sourced from the third-party pricing services. The following table summarizes the change in the fair value of our Level 3 financial instrument: (in thousands) Derivative Liability Fair value as of December 31, 2020 $ 3,081 Change in fair value 59 Fair value as of March 31, 2021 $ 3,140 The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment ( Note 7 ). Generally, increases or decreases in these unobservable inputs would result in a directionally similar impact to the fair value measurement of this derivative instrument. The significant unobservable inputs used in the fair value measurement of the product approval payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment. The fair value of the 2027 Notes ( Note 9

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Teoxane Agreement We entered into an exclusive distribution agreement (the “Teoxane Agreement”) with Teoxane SA (“Teoxane”) in January 2020, pursuant to which Teoxane granted us the exclusive right to import, market, promote, sell and distribute Teoxane’s line of RHA® dermal fillers in exchange for 2,500,000 shares of our common stock and certain other commitments by us. The Teoxane Agreement is effective for a term of ten years from product launch in September 2020 and may be extended for a two-year period upon the mutual agreement of the parties. We are required to meet certain minimum purchase obligations during each year of the term and are required to meet certain minimum expenditure requirements in connection with commercialization efforts unless prevented by certain conditions such as manufacturing delays. Either party may terminate the Teoxane Agreement in the event of the insolvency of, or a material breach by, the other party, including certain specified breaches that include the right for Teoxane to terminate the Teoxane Agreement for our failure to meet the minimum purchase requirements or commercialization expenditure during specified periods, or for our breach of the exclusivity obligations under the Teoxane Agreement. Other Purchase Commitments Under the ABPS Amendment, we are subject to minimum purchase obligations to ABPS of $8.0 million for the year ending in December 31, 2021, and $30.0 million for each of the years ending December 31, 2022, 2023 and 2024. Each party has the right to terminate the ABPS Amendment, without cause, with an 18-month written notice to the other party. In December 2020, we renewed and entered into a supply agreement with Bachem Americas, Inc. (“Bachem”) under which Bachem will supply us peptide raw materials based on the price set in the agreement and in accordance with certain specifications. The initial term of the supply agreement is three years, with automatic renewal for one year unless either company provides written notice 90 days before the end of initial term. We are subject to the minimum order amount of $3.3 million during the term of the supply agreement and additional $1.2 million for the one-year renewal term. Other Contingencies We are obligated to make a $2.0 million milestone payment to a developer of botulinum toxin, List Biological Laboratories, Inc. (“List Laboratories”) upon achievement of a certain regulatory milestone . As of March 31, 2021, the milestone had not been achieved. We are also obligated to pay royalties to List Laboratories on future sales of botulinum toxin products. We entered into an asset purchase agreement with Botulinum Toxin Research Associates, Inc. (“BTRX”), under which we are obligated to pay up to $16.0 million to BTRX upon the satisfaction of milestones relating to our product revenue, intellectual property, and clinical and regulatory events. As of March 31, 2021, a one-time intellectual property development milestone liability of $1.0 million has been recorded in accruals on our condensed consolidated balance sheets. Indemnification We have standard indemnification agreements in the ordinary course of business. Under these indemnification agreements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to our technology. The term of these indemnification agreements is generally perpetual after the execution of the agreements. The maximum potential amount of future payments we are obligated to pay under these indemnification agreements is not determinable because it involves claims that may be made against us in the future but have not been made. We have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. We have indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. For the three months ended March 31, 2021, no amounts associated with the indemnification agreements have been recorded.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Segment Information	Segment Information Reportable Segments We report segment information based on the management approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of our reportable segments. As a result of the HintMD Acquisition in July 2020, we now have two reportable segments: the Product Segment and the Service Segment. Each reportable segment represents a component, or an operating segment, for which separate financial information is available that is utilized on a regular basis by our chief operating decision maker (CODM) in determining resource allocations and performance evaluation. We also considered whether the identified operating segments should be further aggregated based on factors including economic characteristics, the nature of products and services, production processes, customer base, distribution methods, and regulatory environment; however, no such aggregation was made due to dissimilarity of the operating segments. Product Segment Our Product Segment refers to the business that includes the research and development of innovative aesthetic and therapeutic products, including DaxibotulinumtoxinA for Injection for various indications, the U.S. distribution of the RHA® Collection of dermal fillers, and the onabotulinumtoxinA biosimilar program in partnership with Viatris. Both product and collaboration revenues and related expenses are included in Product Segment. Service Segment Our Service Segment refers to the business of payment facilitation, integrated smart payment, subscription and other value-added services through our HintMD fintech platform. Corporate and other expenses include operating expense related to general and administrative expenses, depreciation and amortization, stock-based compensation, and in-process research and development that are not used in evaluating the results of, or in allocating resources to, our segments. There was no inter-segment revenue for the three months ended March 31, 2021 and 2020. Reconciliation of Segment Revenue to Consolidated Revenue Three Months Ended March 31, (in thousands) 2021 2020 Revenue: Product Segment $ 13,158 $ 58 Service Segment 141 — Total revenue $ 13,299 $ 58 Reconciliation of Segment Loss from Operations to Consolidated Loss from Operations Three Months Ended March 31, (in thousands) 2021 2020 Loss from operations: Product Segment $ (37,285) $ (44,467) Service Segment (3,975) — Corporate and other expenses (28,752) (16,493) Total loss from operations $ (70,012) $ (60,960) We do not evaluate performance or allocate resources based on segment asset data, and therefore such information is not presented.

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event LSNE Supply Agreement In April 2021, we and Lyophilization Services of New England, Inc., a contract development and manufacturing services organization (“LSNE”), entered into a commercial supply agreement (the “LSNE Agreement”) pursuant to which LSNE would serve as a non-exclusive manufacturer and supplier of our anticipated products currently under development (the “Products”). The LSNE Agreement provides us with an additional source of manufacturing to support clinical development and commercialization of the Products to potentially mitigate supply chain risk. Pursuant to the LSNE Agreement, we will be responsible for an estimated $28.0 million in costs associated with the design, equipment procurement and validation and facilities-related costs, which would be paid in accordance with a payment schedule based on the completion of specified milestones. The initial term of the LSNE Agreement is dependent upon the date of regulatory submission for the applicable Product and may be sooner terminated by either party in accordance with the terms of the LSNE Agreement. The term of the LSNE Agreement may also be extended by mutual agreement of the parties. The LSNE Agreement also sets forth, among other things, our purchase requirements, pricing and payment information, deliverables, timelines, milestones, payment schedules, manufacturing facility obligations and development of a drug manufacturing process. The parties would also enter into quality agreements and other supplements which detail the process and product specifications for the applicable Product. We are currently evaluating the accounting for the LSNE Agreement.

The Company and Summary of Si_2

The Company and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. Our condensed consolidated balance sheet for the year ended December 31, 2020 was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2021, or any other future period. Our condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission (the “SEC”), on February 25, 2021. Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. All intercompany transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, the fair value of assets and liabilities assumed in business combinations, incremental borrowing rate used to measure operating lease liabilities, the recoverability of goodwill and long-lived assets, useful lives associated with property and equipment and intangible assets, period of benefit associated with deferred costs, useful lives of customer contracts, revenue recognition (including the timing of satisfaction of performance obligations, estimating variable consideration, estimating stand-alone selling prices of promised goods and services, and allocation of transaction price to performance obligations), deferred revenue classification, accruals including clinical trial costs, valuation and assumptions underlying stock-based compensation and other equity instruments, fair value of derivative liability, fair value of the liability component of the convertible senior notes, allocation of purchase consideration in asset acquisitions, and income taxes. The ongoing COVID-19 pandemic has caused a global slowdown of economic activity which has negatively impacted consumer spending, including with respect to our current and potential customers, while also disrupting sales channels and marketing activities. In November 2020, the FDA deferred a decision on the biologics license application (“BLA”) for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines. The FDA reiterated that an inspection of our manufacturing facility is required as part of the BLA approval process, but the FDA was unable to conduct the required inspection of our manufacturing facility in Newark, California, due to the FDA’s travel restrictions associated with the COVID-19 pandemic. We are unable to predict the future impact of the COVID-19 pandemic on the FDA inspection required for the approval of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines, the progress of clinical trials, supplies and sales of the RHA® Collection of dermal fillers, demand for our products and other aspects of our operations. As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.
Recently Adopted Accounting Pronouncement and Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncement In August 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . The amendments in ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 simplifies the accounting for convertible debt instruments by removing certain requirements to separately account for conversion options embedded in debt instruments that are not required to be accounted for as derivative instruments. ASU 2020-06 also updates and improves the consistency of earnings per share calculations for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. On January 1, 2021, we adopted ASU 2020-06 using the modified retrospective method and the adoption did not have any impact for our consolidated balance sheets as of December 31, 2020. As a result of the adoption, on January 1, 2021, we made certain adjustments on our consolidated balance sheets which consisted of an increase of $98.9 million in Convertible Senior Notes (the 2027 Notes as defined in Note 9 ), a decrease of $108.5 million in Additional Paid-in Capital and a decrease of $9.7 million in Accumulated Deficit. Additionally, from January 1, 2021, we will no longer incur non-cash interest expense for the amortization of debt discount after adoption, therefore the interest expense for the 2027 Notes, which is included in the Interest Expense on the condensed consolidated statements of operations and comprehensive loss, will be lower comparing to fiscal year 2020. Recent Accounting Pronouncements The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables present our revenues disaggregated by the timing of transfer of goods or services: Three Months Ended March 31, 2021 (in thousands) Product Revenue Collaboration Revenue Service Revenue Total Timing of revenue recognition: Transferred at a point in time $ 11,647 $ — $ — $ 11,647 Transferred over time — 1,511 141 1,652 Total $ 11,647 $ 1,511 $ 141 $ 13,299

Cash Equivalents and Short-Te_2

Cash Equivalents and Short-Term Investments (Tables)	3 Months Ended
	Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities	The following table is a summary our cash equivalents and short-term investments: March 31, 2021 December 31, 2020 in thousands Cost Fair Value Cost Fair Value Money market funds $ 243,266 $ 243,266 $ 267,130 $ 267,130 Commercial paper 137,386 137,386 113,446 113,446 Total cash equivalents and available-for-sale securities $ 380,652 $ 380,652 $ 380,576 $ 380,576 Classified as: Cash equivalents $ 243,266 $ 277,629 Short-term investments 137,386 102,947 Total cash equivalents and available-for-sale securities $ 380,652 $ 380,576

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Acquired Finite-Lived Intangible Assets by Major Class	The following table sets forth the intangible assets and the remaining useful lives for the intangible assets: March 31, 2021 December 31, 2020 (in thousands, except for in years) Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Distribution rights 3.2 $ 32,334 $ (6,736) $ 25,598 3.4 $ 32,334 $ (4,715) $ 27,619 Developed technology 5.3 19,600 (2,178) 17,422 5.6 19,600 (1,362) 18,238 In-process research and development (1) N/A 16,200 — 16,200 N/A 16,200 — 16,200 Customer relationships 3.3 10,300 (1,717) 8,583 3.6 10,300 (1,072) 9,228 Tradename 0.3 100 (66) 34 0.6 100 (42) 58 Total intangible assets $ 78,534 $ (10,697) $ 67,837 $ 78,534 $ (7,191) $ 71,343 (1) In-process research and development relates to the research and development of payment facilitator technology to facilitate the processing of customer payments. As of March 31, 2021, no amortization expense has been recorded as the assets have not yet been completed and placed into service. Upon completion of the associated research and development activities, the assets' useful lives will be determined. Prior to completion of certain research and development activities, these intangible assets will be subject to annual impairment tests, or more frequent tests in the event of any impairment indicators occurring. These impairment tests require significant judgment regarding the status of the research activities, the potential for future revenues to be derived from any products that may result from those activities, and other factors.
Schedule of Acquired Indefinite-lived Intangible Assets by Major Class	The following table sets forth the intangible assets and the remaining useful lives for the intangible assets: March 31, 2021 December 31, 2020 (in thousands, except for in years) Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Distribution rights 3.2 $ 32,334 $ (6,736) $ 25,598 3.4 $ 32,334 $ (4,715) $ 27,619 Developed technology 5.3 19,600 (2,178) 17,422 5.6 19,600 (1,362) 18,238 In-process research and development (1) N/A 16,200 — 16,200 N/A 16,200 — 16,200 Customer relationships 3.3 10,300 (1,717) 8,583 3.6 10,300 (1,072) 9,228 Tradename 0.3 100 (66) 34 0.6 100 (42) 58 Total intangible assets $ 78,534 $ (10,697) $ 67,837 $ 78,534 $ (7,191) $ 71,343 (1) In-process research and development relates to the research and development of payment facilitator technology to facilitate the processing of customer payments. As of March 31, 2021, no amortization expense has been recorded as the assets have not yet been completed and placed into service. Upon completion of the associated research and development activities, the assets' useful lives will be determined. Prior to completion of certain research and development activities, these intangible assets will be subject to annual impairment tests, or more frequent tests in the event of any impairment indicators occurring. These impairment tests require significant judgment regarding the status of the research activities, the potential for future revenues to be derived from any products that may result from those activities, and other factors.
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Based on the amount of intangible assets subject to amortization as of March 31, 2021, the estimated amortization expense for each of the next five fiscal years and thereafter was as follows: Year Ending December 31, (in thousands) 2021 remaining nine months $ 10,477 2022 13,925 2023 13,925 2024 8,137 2025 3,267 2026 and thereafter 1,906 Total $ 51,637

Balance Sheet Components (Table

Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accruals and other current liabilities consist of the following: March 31, December 31, (in thousands) 2021 2020 Accruals related to: Compensation $ 13,940 $ 17,374 General expenses 6,052 5,683 Clinical trials 3,052 3,726 Interest expense 629 1,887 Inventories 215 1,796 Other current liabilities 2,213 1,472 Nonrecurring milestone payment 1,000 1,000 Total $ 27,101 $ 32,938
Schedule of Property and Equipment, Net	Property and equipment, net consists of the following: March 31, December 31, (in thousands) 2021 2020 Manufacturing equipment $ 19,937 $ 19,810 Leasehold improvements 5,978 5,972 Platform software (1) 5,369 3,388 Other construction in progress 3,210 1,539 Computer software 2,972 2,972 Computer equipment 1,909 1,768 Furniture and fixtures 1,616 1,541 Total property and equipment 40,991 36,990 Less: Accumulated depreciation and amortization (20,225) (19,491) Property and equipment, net $ 20,766 $ 17,499 (1) The platform software was not placed in service as of both March 31, 2021 and December 31, 2020.

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Operating Lease Costs	The operating lease costs are summarized as follows: Three Months Ended March 31, (in thousands) 2021 2020 Operating lease cost $ 1,704 $ 1,425 Variable lease cost (1) 283 77 Total operating lease costs $ 1,987 $ 1,502 (1) Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.
Operating Lease Liability Maturities	As of March 31, 2021, maturities of our operating lease liabilities are as follows: Year Ending December 31, (in thousands) 2021 remaining nine months $ 5,888 2022 6,613 2023 6,741 2024 6,952 2025 7,165 2026 and thereafter 8,003 Total operating lease payments 41,362 Less imputed interest (1) (10,689) Present value of operating lease payments $ 30,673
Supplemental Cash Flow Information	Supplemental cash flow information related to the operating leases was as follows: Three Months Ended March 31, (in thousands) 2021 2020 Cash paid for amounts included in the measurement of operating lease liabilities $ 1,761 $ 1,677

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Convertible Debt	Interest expense relating to the 2027 Notes in the condensed consolidated statements of operations and comprehensive loss are summarized as follows: Three Months Ended (in thousands) March 31, 2021 March 31, 2020 Contractual interest expense $ 1,258 $ 643 Amortization of debt issuance costs 310 44 Amortization of debt discount (1) — 1,461 Total interest expense $ 1,568 $ 2,148 (1) The effective interest rate on the liability component of the 2027 Notes was 9.5% for the year ended December 31, 2020, which remained unchanged from the issuance date. As of December 31, 2020, the unamortized debt discount was $101.7 million and will be amortized over 6.1 years. Due to the adoption of ASU 2020-06 ( Note 1 ), debt discount was eliminated on January 1, 2021 therefore we no longer amortize debt discount. As of March 31, 2021 and December 31, 2020, the convertible senior notes on the condensed consolidated balance sheet represented the carrying amount of the liability component of the 2027 Notes, net of unamortized debt discounts and debt issuance costs (as applicable), which are summarized as follows: March 31, December 31, (in thousands) 2021 2020 2027 Notes $ 287,500 $ 287,500 Less: Unamortized debt issuance costs (7,806) (5,275) Less: Unamortized debt discount — (101,699) Carrying amount of 2027 Notes $ 279,694 $ 180,526

Stockholders' Equity and Stoc_2

Stockholders' Equity and Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Summary of Common Stock Equivalents Excluded From Computation of Diluted Net Income (Loss) Per Share	Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below: March 31, 2021 2020 Convertible senior notes 8,878,938 8,878,938 Outstanding common stock options 5,004,596 5,305,185 Unvested restricted stock awards and performance stock awards 4,083,686 2,799,982 Shares of common stock expected to be purchased on June 30 under the 2014 ESPP 100,769 49,861
Schedule of Stock-based Compensation Expense	Stock-based compensation expense was allocated as follows: (in thousands) Three Months Ended March 31, 2021 2020 Selling, general and administrative $ 7,281 $ 4,102 Research and development 3,326 2,442 Total stock-based compensation $ 10,607 $ 6,544

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Instruments	The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy. March 31, 2021 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 243,266 $ 243,266 $ — $ — Commercial paper 137,386 — 137,386 — Total assets measured at fair value $ 380,652 $ 243,266 $ 137,386 $ — Liabilities Derivative liability $ 3,140 $ — $ — $ 3,140 Total liabilities measured at fair value $ 3,140 $ — $ — $ 3,140 December 31, 2020 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 267,130 $ 267,130 $ — $ — Commercial paper 113,446 — 113,446 — Total assets measured at fair value $ 380,576 $ 267,130 $ 113,446 $ — Liabilities Derivative liability $ 3,081 $ — $ — $ 3,081 Total liabilities measured at fair value $ 3,081 $ — $ — $ 3,081
Summary of Changes in Fair Value of Financial Instruments	The following table summarizes the change in the fair value of our Level 3 financial instrument: (in thousands) Derivative Liability Fair value as of December 31, 2020 $ 3,081 Change in fair value 59 Fair value as of March 31, 2021 $ 3,140

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Reconciliation of Segment Revenue to Consolidated Revenue	Reconciliation of Segment Revenue to Consolidated Revenue Three Months Ended March 31, (in thousands) 2021 2020 Revenue: Product Segment $ 13,158 $ 58 Service Segment 141 — Total revenue $ 13,299 $ 58
Reconciliation of Segment Loss From Operations to Consolidated Loss From Operations	Reconciliation of Segment Loss from Operations to Consolidated Loss from Operations Three Months Ended March 31, (in thousands) 2021 2020 Loss from operations: Product Segment $ (37,285) $ (44,467) Service Segment (3,975) — Corporate and other expenses (28,752) (16,493) Total loss from operations $ (70,012) $ (60,960)

The Company and Summary of Si_3

The Company and Summary of Significant Accounting Policies- Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Net loss	$ 71,639	$ 61,933
Working capital surplus	355,600
Accumulated deficit	1,188,281		$ 1,126,293
Cash, cash equivalents and investments	$ 386,800
Minimum period expected to be funded by existing capital resources	12 months
Cumulative Effect, Period of Adoption, Adjustment
Property, Plant and Equipment [Line Items]
Accumulated deficit	$ (9,700)
Convertible debt	98,900
Decrease in additional paid in capital	$ 108,500

Revenue -Revenues Disaggregated

Revenue -Revenues Disaggregated by Timing of Transfer of Goods or Services (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	$ 13,299	$ 58
Transferred at a point in time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	11,647
Transferred over time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	1,652
Product revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	11,647	0
Product revenue | Transferred at a point in time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	11,647
Product revenue | Transferred over time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	0
Collaboration revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	1,511	58
Collaboration revenue | Transferred at a point in time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	0
Collaboration revenue | Transferred over time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	1,511
Service revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	141	$ 0
Service revenue | Transferred at a point in time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	0
Service revenue | Transferred over time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	$ 141

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	$ 13,299,000	$ 58,000
Remaining performance obligation	31,000,000
Deferred revenue, current portion	9,046,000		$ 7,851,000
Deferred revenue, net of current portion	74,967,000		77,294,000
Contract with customer, liability, revenue recognized	0	0
Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	1,500,000	$ 58,000
Deferred revenue, current portion	9,000,000		7,900,000
Deferred revenue, net of current portion	44,000,000		$ 46,300,000
Viatris
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable upfront payment	60,000,000
Contingent payments	70,000,000
Revenue maximum for receipt of tiered milestone payments	225,000,000
Remaining performance obligation	102,700,000
Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent payments	229,500,000
Transferred over time
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenue	$ 1,652,000

Cash Equivalents and Short-Te_3

Cash Equivalents and Short-Term Investments (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Cost	$ 380,652,000	$ 380,576,000
Fair Value	380,652,000	380,576,000
Other-than-temporary impairments on available-for-sale securities	0	0
Cash equivalents
Debt Securities, Available-for-sale [Line Items]
Fair Value	243,266,000	277,629,000
Short-term investments
Debt Securities, Available-for-sale [Line Items]
Fair Value	137,386,000	102,947,000
Money market funds
Debt Securities, Available-for-sale [Line Items]
Cost	243,266,000	267,130,000
Fair Value	243,266,000	267,130,000
Commercial paper
Debt Securities, Available-for-sale [Line Items]
Cost	137,386,000	113,446,000
Fair Value	$ 137,386,000	$ 113,446,000

Intangible Assets, net - Intang

Intangible Assets, net - Intangible Assets and the Remaining Useful Lives (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 78,534	$ 78,534
Accumulated Amortization	(10,697)	(7,191)
Total	51,637
Net Carrying Amount	67,837	71,343
In-process Research and Development
Acquired Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	$ 16,200	$ 16,200
Distribution rights
Acquired Finite-Lived Intangible Assets [Line Items]
Remaining useful lives	3 years 2 months 12 days	3 years 4 months 24 days
Finite-lived intangible assets, gross	$ 32,334	$ 32,334
Accumulated Amortization	(6,736)	(4,715)
Total	$ 25,598	$ 27,619
Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Remaining useful lives	5 years 3 months 18 days	5 years 7 months 6 days
Finite-lived intangible assets, gross	$ 19,600	$ 19,600
Accumulated Amortization	(2,178)	(1,362)
Total	$ 17,422	$ 18,238
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Remaining useful lives	3 years 3 months 18 days	3 years 7 months 6 days
Finite-lived intangible assets, gross	$ 10,300	$ 10,300
Accumulated Amortization	(1,717)	(1,072)
Total	$ 8,583	$ 9,228
Tradename
Acquired Finite-Lived Intangible Assets [Line Items]
Remaining useful lives	3 months 18 days	7 months 6 days
Finite-lived intangible assets, gross	$ 100	$ 100
Accumulated Amortization	(66)	(42)
Total	$ 34	$ 58

Intangible Assets, net - Additi

Intangible Assets, net - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 3,500,000	$ 0
Amortization
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	2,800,000
Selling, general and administrative
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 700,000

Intangible Assets, net - Expect

Intangible Assets, net - Expected Amortization Expense for the Unamortized Acquired Intangible Assets (Details) $ in Thousands	Mar. 31, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021 remaining nine months	$ 10,477
2022	13,925
2023	13,925
2024	8,137
2025	3,267
2026 and thereafter	1,906
Total	$ 51,637

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventories	$ 5,629	$ 5,876

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Compensation	$ 13,940	$ 17,374
General expenses	6,052	5,683
Clinical trials	3,052	3,726
Interest expense	629	1,887
Inventories	215	1,796
Other current liabilities	2,213	1,472
Nonrecurring milestone payment	1,000	1,000
Total	$ 27,101	$ 32,938

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 40,991	$ 36,990
Less: Accumulated depreciation and amortization	(20,225)	(19,491)
Property and equipment, net	20,766	17,499
Manufacturing equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	19,937	19,810
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,978	5,972
Platform software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,369	3,388
Other construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,210	1,539
Computer software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,972	2,972
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,909	1,768
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,616	$ 1,541

Derivative Liability - Addition

Derivative Liability - Additional Information (Details) - Product Approval Payment Derivative - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Valeant Pharmaceuticals International, Inc.
Settlement And Termination [Line Items]
Nonrecurring milestone payment	$ 4
Medicis Pharmaceutical Corporation
Settlement And Termination [Line Items]
Fair value of derivative	$ 3.1	$ 3.1
Medicis Pharmaceutical Corporation | Measurement Input, Expected Term
Settlement And Termination [Line Items]
Fair value, measurement input, duration	3 months 18 days	6 months
Medicis Pharmaceutical Corporation | Measurement Input, Risk Free Interest Rate
Settlement And Termination [Line Items]
Fair value, measurement input (percent)	0.03%	0.10%
Medicis Pharmaceutical Corporation | Measurement Input, Entity Credit Risk
Settlement And Termination [Line Items]
Fair value, measurement input (percent)	7.50%	7.50%

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)option_to_extend_lease_term
Leases [Abstract]
Weighted average remaining lease term	5 years 9 months 18 days
Extended term of lease	14 years
Initial lease term	150 months
Number of option to extend lease facility | option_to_extend_lease_term	1
Renewal term	7 years
Lessee, operating lease, lease not yet commenced, amount | $	$ 22.9

Leases - Operating Lease Costs

Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Operating lease cost	$ 1,704	$ 1,425
Variable lease cost	283	77
Total operating lease costs	$ 1,987	$ 1,502

Leases - Operating Lease Liabil

Leases - Operating Lease Liability Maturities (Details) $ in Thousands	Mar. 31, 2021USD ($)
Leases [Abstract]
2021 remaining nine months	$ 5,888
2022	6,613
2023	6,741
2024	6,952
2025	7,165
2026 and thereafter	8,003
Total operating lease payments	41,362
Less imputed interest	(10,689)
Present value of operating lease payments	$ 30,673
Weighted average discount rate (percent)	11.40%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 1,761	$ 1,677

Convertible Senior Notes- Addit

Convertible Senior Notes- Additional Information (Details)	Feb. 14, 2020USD ($)trading_day$ / shares	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of convertible senior notes		$ 0	$ 287,500,000
2027 Notes | Convertible Debt
Debt Instrument [Line Items]
Principal amount	$ 287,500,000
Stated percentage	1.75%
Proceeds from issuance of convertible senior notes	$ 278,300,000
Threshold trading days | trading_day	20
Threshold consecutive trading days | trading_day	30
Threshold percentage of stock price trigger	130.00%
Conversion price (in dollars per share) | $ / shares	$ 32.38
Redemption price, percentage	100.00%
Long-term debt	$ 175,400,000	$ 279,694,000		$ 180,526,000
Effective percentage	9.50%			9.50%
Carrying amount of equity component	$ 112,100,000
Debt issuance costs	9,200,000
Debt issuance costs, liability component	5,600,000
Debt issuance costs, equity component	$ 3,600,000
2027 Notes | Convertible Debt | Debt Conversion Terms One
Debt Instrument [Line Items]
Threshold trading days | trading_day	20
Threshold consecutive trading days | trading_day	30
Threshold percentage of stock price trigger	130.00%
2027 Notes | Convertible Debt | Debt Conversion Terms Two
Debt Instrument [Line Items]
Threshold trading days | trading_day	5
Threshold consecutive trading days | trading_day	10
Threshold percentage of stock trading price	98.00%

Convertible Senior Notes - Inte

Convertible Senior Notes - Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Feb. 14, 2020
Debt Instrument [Line Items]
Contractual interest expense	$ 1,258	$ 643
Amortization of debt issuance costs	310	44
Amortization of debt discount	0	1,461
Total interest expense	1,568	$ 2,148
2027 Notes | Convertible Debt
Debt Instrument [Line Items]
Effective percentage			9.50%	9.50%
Less: Unamortized debt discount	$ 0		$ 101,699
Remaining discount amortization period			6 years 1 month 6 days

Convertible Senior Notes - Carr

Convertible Senior Notes - Carrying Amount of Liability Component (Details) - 2027 Notes - Convertible Debt - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Feb. 14, 2020
Debt Instrument [Line Items]
2027 Notes	$ 287,500	$ 287,500
Less: Unamortized debt issuance costs	(7,806)	(5,275)
Less: Unamortized debt discount	0	(101,699)
Carrying amount of 2027 Notes	$ 279,694	$ 180,526	$ 175,400

Convertible Senior Notes - Capp

Convertible Senior Notes - Capped Call Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	Feb. 14, 2020	Mar. 31, 2021	Mar. 31, 2020
Debt Instrument [Line Items]
Payment of capped call transactions	$ 28,900	$ 0	$ 28,865
Price cap (in dollars per share)	$ 48.88
Premium percentage over sale price	100.00%
Number of shares subject to anti-dilution adjustments (in shares)	8.9
2027 Notes | Convertible Debt
Debt Instrument [Line Items]
Conversion price (in dollars per share)	$ 32.38

Stockholders' Equity and Stoc_3

Stockholders' Equity and Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 21, 2021	Nov. 30, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Jan. 01, 2021	Jul. 23, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues (in shares)	0
Proceeds from issuance of common stock in connection with at-the-market offerings, net of commissions			$ 21,706	$ 0
Follow on Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)		$ 0.001
At the Market Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			32,600,000
Stock issuance sales agreement, authorized offering price, maximum		$ 125,000
Sale of stock, issuance costs, commission, percentage, maximum		3.00%
Stock issued during period, shares, new issues (in shares)			761,526		2,585,628
Proceeds from issuance of common stock in connection with at-the-market offerings, net of commissions			$ 21,700		$ 68,200
At the Market Offering | Weighted Average
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)			$ 29.09		$ 27.18
2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			2,492,257			2,767,146
2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			485,425
2017 Equity Incentive Plan, HintMD Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			427,313
Shares underlying stock options granted (in shares)			0
Shares granted under restricted stock awards (in shares)			0
2017 Equity Incentive Plan, HintMD Plan | HintMD
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant							1,260,946
2014 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)						300,000
Share-based Payment Arrangement | 2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares underlying stock options granted (in shares)			501,982
Restricted Stock | 2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted under restricted stock awards (in shares)			932,827
Performance-based Common Stock | 2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted under restricted stock awards (in shares)			234,350
Employee Stock Option | 2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares underlying stock options granted (in shares)			104,090
Employee Stock | 2014 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			1,909,800

Stockholders' Equity and Stoc_4

Stockholders' Equity and Stock-Based Compensation - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Convertible senior notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	8,878,938	8,878,938
Outstanding common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	5,004,596	5,305,185
Unvested restricted stock awards and performance stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	4,083,686	2,799,982
Shares of common stock expected to be purchased on June 30 under the 2014 ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	100,769	49,861

Stockholders' Equity and Stoc_5

Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 10,607	$ 6,544
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	7,281	4,102
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 3,326	$ 2,442

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Details) - Recurring - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	$ 380,652	$ 380,576
Total liabilities measured at fair value	3,140	3,081
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	243,266	267,130
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	137,386	113,446
Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	3,140	3,081
Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	243,266	267,130
Total liabilities measured at fair value	0	0
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	243,266	267,130
Level 1 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 1 | Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	137,386	113,446
Total liabilities measured at fair value	0	0
Level 2 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 2 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	137,386	113,446
Level 2 | Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Total liabilities measured at fair value	3,140	3,081
Level 3 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 3 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 3 | Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	$ 3,140	$ 3,081

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Convertible debt, fair value disclosures	$ 325,900	$ 326,200
Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value as of December 31, 2020	3,081
Change in fair value	59
Fair value as of March 31, 2021	$ 3,140

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Dec. 31, 2020	Jan. 31, 2020	Mar. 31, 2021	Dec. 31, 2020
Loss Contingencies [Line Items]
Purchase obligation, to be paid, remainder of fiscal year			$ 8,000,000
Purchase obligation, to be paid, year one			30,000,000
Purchase obligation, to be paid, year two			30,000,000
Purchase obligation, to be paid, year three			30,000,000
Supply commitment, remaining minimum amount committed	$ 3,300,000			$ 3,300,000
Supply commitment, additional amount committed	$ 1,200,000			$ 1,200,000
Payment arrangement renewal term				1 year
Indemnification liability recorded during the period			$ 0
Term Of Written Notice			18 months
Purchase Agreement Term	3 years
Other Current Liabilities
Loss Contingencies [Line Items]
Fair value of assets acquired			$ 1,000,000
Botulinum Toxin Research Associates, Inc.
Loss Contingencies [Line Items]
Accrued milestone obligations			$ 16,000,000
Teoxane Agreement
Loss Contingencies [Line Items]
Issuance of common stock in connection with the teoxane agreement (in shares)		2,500,000
Collaborative agreement, contractual period			10 years
Collaborative agreement, extended contractual period			2 years
List Laboratories | Product Approval Payment Derivative
Loss Contingencies [Line Items]
Accrued milestone obligations			$ 2,000,000

Segment Information - Reconcili

Segment Information - Reconciliation of Segment Revenue to Consolidated Revenue (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)segment	Mar. 31, 2020USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment	2
Segment Reporting Information [Line Items]
Total Revenue	$ 13,299	$ 58
Product Segment
Segment Reporting Information [Line Items]
Total Revenue	13,158	58
Service Segment
Segment Reporting Information [Line Items]
Total Revenue	$ 141	$ 0

Segment Information - Reconci_2

Segment Information - Reconciliation of Segment Loss from Operations to Consolidated Loss from Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting Information [Line Items]
Total loss from operations	$ (70,012)	$ (60,960)
Corporate and other expenses
Segment Reporting Information [Line Items]
Total loss from operations	(28,752)	(16,493)
Product Segment | Operating Segments
Segment Reporting Information [Line Items]
Total loss from operations	(37,285)	(44,467)
Service Segment | Operating Segments
Segment Reporting Information [Line Items]
Total loss from operations	$ (3,975)	$ 0

Subsequent Event (Details)

Subsequent Event (Details) $ in Millions	1 Months Ended
	Apr. 30, 2021USD ($)
Subsequent Event | Collaborative Arrangement
Subsequent Event [Line Items]
Supply agreement, estimated future milestone cost	$ 28